Form D · Biotechnology
Eledon Pharmaceuticals, Inc.
Irvine, CA · CIK 0001404281
Offering snapshot reported May 23, 2024 · SEC filing
- Reported sold
- $50M Indefinite offering
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 9, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 23, 2024 | Initial | $49,999,010 | No comparison | 24 | SEC filing |
| May 22, 2023 | Initial | $35,000,000 | No comparison | 38 | SEC filing |
| Sep 25, 2020 | Initial | $108,144,151 | No comparison | 35 | SEC filing |
| Jan 27, 2020 | Initial | $862,278 | No comparison | 10 | SEC filing |
| May 10, 2019 | Initial | $862,278 | No comparison | 10 | SEC filing |
| May 15, 2013 | Initial | $19,999,993 | No comparison | 19 | SEC filing |
| Sep 20, 2011 | Initial | $1,892,794 | No comparison | 6 | SEC filing |
| May 6, 2009 | Initial | $10,000,000 | No comparison | Not reported | SEC filing |
| Oct 27, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 18, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.62M
- Finders' fees
- $0
- Form D file number
- 021-514042
$49,999,010.48 of common stock and pre-funded warrants sold; plus $7,989.52 assuming exercise of all pre-funded warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 39011 | |
| Noble Capital Markets, Inc. | 15768 |
Source: Form D, filed May 23, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Reinhard J. Ambros | Director |
| Timothy J. Barberich | Director |
| Scott Chappel | Executive |
| Erez Chimovits | Director |
| Cheryl Cohen | Director |
| Gregory Flesher | Director, Executive |
| David Alexandre Gros | Director, Executive |
| Seth L. Harrison | Director |
| Jan Hillson | Director |
| Keith Katkin | Director |
| David A. Kessler | Director |
| Allan Kirk | Director |
| Jon Kuwahara | Executive |
| June Lee | Director |
| Paul Little | Executive |
| Gary Lyons | Director |
| John Mc Bride | Director |
| Jodie P. Morrison | Executive |
| Campbell Murray | Director |
| Walter Ogier | Director |
| Steven Perrin | Director, Executive |
| James Robinson | Director |
| Bryan Smith | Executive |
| Catherine Turkel | Executive |
| Joseph A. Yanchik, Iii | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
19800 Macarthur Blvd. Suite 250
Irvine, CA, 92612
Irvine, CA, 92612